A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study

Journal of the American College of Cardiology

Volumn 33, Issue 7, 1999, Pages 1879-1885

  Jang, Ik Kyung ^a   Brown, David F M ^a   Giugliano, Robert P ^a   Anderson, H Vernon ^b   Losordo, Douglas ^c   Nicolau, Jose C ^d   Dutra, Oscar P ^e   Bazzino, Oscar ^f   Viamonte, Victor Molina ^g   Norbady, Roberto ^h   Liprandi, Alvaro Sosa ⁱ   Massey, Thomas J ^j   Dinsmore, Robert ^a   Schwarz Jr, Richard P ^k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TEXAS HEART INSTITUTE   (United States)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

^d Instituto de Molestias Cardiovasculares   (Brazil)

^e INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g HOSPITAL ESPAÑOL   (Argentina)

^h HOSPITAL FRANCÉS   (Argentina)

ⁱ Sanatorio Mitre   (Argentina)

^j Coromed Inc ^*  (United States)

^k TEXAS BIOTECHNOLOGY CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; CHEMOTHERAPY, ADJUVANT; CORONARY ANGIOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SINGLE-BLIND METHOD; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0032694598     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00107-2     Document Type: Article

References (25)

1. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival should the paradigm be expanded? [Editorial] Circulation. 79:1989;441-444.
2. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
3. Neuhaus K.-L., von Essen R., Tebbe U., et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase results of the rt-PA-APSAC Patency Study (TAPS) . J Am Coll Cardiol. 19:1992;885-891.
4. Cannon C.P., McCabe C.H., Diver D.J., et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, antistreplase and combination thrombolytic therapy for acute myocardial infarction results of the Thrombolysis is Myocardial Infarction (TIMI) 4 Trial . J Am Coll Cardiol. 24:1994;1602-1610.
5. Ohman E.M., Califf R.M., Topol E.F., et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 82:1990;781-791.
6. Indications for fibrinolytic therapy in suspected acute myocardial infarction collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients . Lancet. 1:1994;397-402.
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
8. Hsia J., Hamilton W.P., Kleiman N., et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 323:1990;1433-1437.
9. Bleich S.D., Nichols T.C., Schumacher R.R., et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 66:1990;1412-1417.
10. Berry C.N., Girardot C., Lecoffre C., Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin comparison with heparin and recombinant hirudin . Throm Haemost. 72:1994;381-386.
11. Lunven C., Gauffeny C., Lecoffre C., et al. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost. 75:1996;455-458.
12. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
13. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 94:1996;911-921.
14. Boeve T.J., Reed G.L., Carias de Oliveria N., et al. Comparison of argatroban and hirudin for the reperfusion of thrombotic arterial occlusion by tissue plasminogen activator. J Thromb Thrombol. 5:1998;103-108.
15. Jang I.K., Gold H.K., Leinbach R.C., et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 67:1990;1552-1561.
16. Jang I.K., Gold H.K., Ziskind A.A., et al. Prevention of platelet-rich arterial thrombosis by thrombin inhibition. Circulation. 81:1990;219-225.
17. Jang I.K., Gold H.K., Leinbach R.C., et al. Persistent inhibition of arterial thrombosis by a one hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis. 3:1992;407-414.
18. Kikumoto R., Tamao Y., Tezuka T., et al. Selective inhibition of thrombin by (2R, 4R)-4 methyl-1-[N2-(3-methy-1,2,3,4-tetrahydro-8-quinolinesulfony)-1-arginyl]-2- piperidinecarboxylic acid. Biochemistry. 23:1984;85-90.
19. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count. A quantitative method of assessing coronary artery flow. Circulation. 93:1996;879-888.
20. Theroux P., Perez-Villa F., Waters D., Lesperance J., et al. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 91:1995;2132-2139.
21. White H.D., Aylward P.E., Frey M.J., et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 96:1997;2155-2161.
22. A randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 90:1994;1631-1637.
23. Antman E.M. Hirudin in acute myocardial infarction safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial . Circulation. 90:1994;1624-1630.
24. Griffin J.H. Blood coagulation the thrombin paradox . Nature. 378:1995;337-338.
25. Topol E.J., Fuster V., Harrington R.A., et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation. 89:1994;1557-1566.